MG
SPRY icon

Michael Gelband’s ARS Pharmaceuticals SPRY Stock Holding History

Michael Gelband’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-96,093
Closed -$772K – 2034
2026
Q1 		$772K Buy
+96,093
New +$921K 0.01% 1070
2025
Q3 		– Sell
-18,217
Closed -$318K – 1987
2025
Q2 		$318K Sell
18,217
-179,318
-91% -$2.59M ﹤0.01% 1235
2025
Q1 		$2.48M Buy
197,535
+172,907
+702% +$2.08M 0.02% 624
2024
Q4 		$260K Buy
+24,628
New +$345K ﹤0.01% 1317
2024
Q1 		– Sell
-38,022
Closed -$208K – 1939
2023
Q4 		$208K Buy
38,022
+26,992
+245% +$118K ﹤0.01% 1271
2023
Q3 		$42K Buy
+11,030
New +$72.4K ﹤0.01% 1616
2022
Q1 		– Sell
-19,148
Closed -$128K – 2645
2021
Q4 		$128K Buy
+19,148
New +$156K ﹤0.01% 1915
2021
Q1 		– Sell
-20,882
Closed -$968K – 2572
2020
Q4 		$968K Buy
+20,882
New +$697K 0.01% 873

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Michael Gelband's SPRY Position: Q2 2026 in Review

Michael Gelband sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 96,093 shares — an estimated $772K sold.

Michael Gelband first reported a position in SPRY in Q4 2020 and held it in 8 quarters. The position peaked at $2.48M in Q1 2025. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Michael Gelband reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 96,093 ARS Pharmaceuticals shares in Q2 2026, an estimated $772K.
  • Michael Gelband first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • Michael Gelband's ARS Pharmaceuticals position peaked at $2.48M in Q1 2025.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.